

![]() |
Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial |
|
Authors | ![]() | |
Published in | Journal of thrombosis and haemostasis. 2015, vol. 13, no. 4, p. 520-529 | |
Abstract | Case reports on recombinant human factor VIIa (rhuFVIIa) use in women with severe postpartum hemorrhage (PPH) showed encouraging results, but no randomized controlled trial (RCT) is available. | |
Keywords | Adult — Coagulants/administration & dosage/adverse effects/therapeutic use — Compassionate Use Trials — Dinoprostone/analogs & derivatives/therapeutic use — Drug Administration Schedule — Factor VIII/administration & dosage/adverse effects/therapeutic use — Female — France — Hemostatic Techniques/adverse effects — Humans — Hysterectomy — Infusions, Intravenous — Postpartum Hemorrhage/diagnosis/drug therapy/mortality — Pregnancy — Risk Factors — Severity of Illness Index — Switzerland — Time Factors — Treatment Failure — Venous Thrombosis/chemically induced | |
Identifiers | DOI: 10.1111/jth.12844 PMID: 25594352 | |
Full text | ||
Structures | ||
Research group | Geneva Platelet Group (13) | |
Citation (ISO format) | LAVIGNE-LISSALDE, G et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. In: Journal of thrombosis and haemostasis, 2015, vol. 13, n° 4, p. 520-529. doi: 10.1111/jth.12844 https://archive-ouverte.unige.ch/unige:89774 |